Deep Intelligent Pharma closes $40M series funding to accelerate AGI brain-like model R&D
Recently, Deep Intelligent Pharma, a globally leading AI unicorn, announced the completion of a new financing round totaling $40 million. This round saw continued investment from existing shareholders, including CDH Baifu, Xinding Capital, Jinyi Capital, and Kaitai Capital, with Index Capital once again serving as the exclusive financial advisor.
Previously, Deep Intelligent Pharma completed a $50 million Series D financing in December 2025, followed by another $60 million financing in February 2026. This latest $40 million round comes just one month after the previous financing, bringing the total funds raised over three months to $150 million. The participation of numerous leading institutional investors fully demonstrates the capital market's strong recognition of and long-term confidence in Deep Intelligent Pharma's AI-driven "Life Sciences + Material Sciences" dual-engine strategy.
Since its founding in 2017, Deep Intelligent Pharma has consistently stood at the forefront of the intersection between artificial intelligence and science. In the life sciences sector, Deep Intelligent Pharma pioneered an original organizational model—the "AI Bionic Brain + Expert" native model—substituting computing power for human labor stacking. Based on underlying scientific mechanisms, this approach dramatically compresses clinical trial timelines, including clinical protocol design cycles and statistical analysis cycles, achieving a dual leap in both efficiency and precision, thereby redefining the AI CRO landscape.
In the material sciences sector, Deep Intelligent Pharma has innovatively transferred the computational complexity paradigms from life sciences to material science. By constructing the MateriaOS engine based on bionics, it has established a "digital wormhole" connecting the microscopic quantum world with macroscopic industrial applications. Leveraging multi-scale modeling, molecular dynamics simulations, and generative artificial intelligence—core competencies honed in the life sciences field—Deep Intelligent Pharma has built a unified computational framework covering the entire chain from atoms to molecules to materials to devices. This breaks through the efficiency ceiling of traditional "trial and error" material development methods, transforming the microscopic complexity of biological computation into predictive accuracy for material design, achieving a paradigm shift from "discovering materials" to "creating materials."
Its modular architecture supports cross-domain knowledge transfer, providing a universal intelligent foundation for upper-layer vertical industry engines. Downstream applications cover strategic sectors including new energy batteries, semiconductor materials, pesticide molecules, and high-temperature resistant alloys.
Image provided by Deep Intelligent Pharma
In this financing round, continued investment from existing shareholders including CDH Baifu, Xinding Capital, Jinyi Capital, and Kaitai Capital not only affirms Deep Intelligent Pharma's past achievements but also represents a firm commitment to its future vision. This fully demonstrates the capital market's confidence in Deep Intelligent Pharma's technological moat, commercialization capabilities, and long-term development potential.
The proceeds from this financing round will be primarily allocated to three key areas: first, advancing the research and development of multi-matrix AGI brain-like models to build a multi-matrix intelligent agent system grounded in life sciences and material sciences; second, deepening global expansion by strengthening technology delivery and business development in core markets including China, Japan, and the United States; and third, expanding the top-tier talent pool by attracting leading global experts at the intersection of artificial intelligence and science.